MA40893B1 - Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées - Google Patents
Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associéesInfo
- Publication number
- MA40893B1 MA40893B1 MA40893A MA40893A MA40893B1 MA 40893 B1 MA40893 B1 MA 40893B1 MA 40893 A MA40893 A MA 40893A MA 40893 A MA40893 A MA 40893A MA 40893 B1 MA40893 B1 MA 40893B1
- Authority
- MA
- Morocco
- Prior art keywords
- hydroxyalkyl substituted
- compounds
- phenyltriazole derivatives
- substituted phenyltriazole
- derivatives
- Prior art date
Links
- 125000002768 hydroxyalkyl group Chemical group 0.000 title abstract 2
- LUEYUHCBBXWTQT-UHFFFAOYSA-N 4-phenyl-2h-triazole Chemical class C1=NNN=C1C1=CC=CC=C1 LUEYUHCBBXWTQT-UHFFFAOYSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000024172 Cardiovascular disease Diseases 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 230000002526 effect on cardiovascular system Effects 0.000 abstract 1
- 208000017169 kidney disease Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D249/10—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D249/12—Oxygen or sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La présente invention concerne de nouveaux dérivés de 5- (hydroxyalkyl) -1-phényl-1,2,4-triazole, des procédés de préparation de tels composés, des compositions pharmaceutiques contenant de tels composés et l'utilisation de tels composés ou compositions. Pour le traitement et / ou la prévention de maladies, en particulier pour le traitement et / ou la prévention de maladies cardiovasculaires et rénales.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP14191491 | 2014-11-03 | ||
| EP15788389.3A EP3215498B1 (fr) | 2014-11-03 | 2015-10-30 | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées |
| PCT/EP2015/075200 WO2016071212A1 (fr) | 2014-11-03 | 2015-10-30 | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA40893A MA40893A (fr) | 2017-09-13 |
| MA40893B1 true MA40893B1 (fr) | 2018-11-30 |
Family
ID=51897095
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA40893A MA40893B1 (fr) | 2014-11-03 | 2015-10-30 | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées |
Country Status (40)
| Country | Link |
|---|---|
| US (2) | US20170313665A1 (fr) |
| EP (1) | EP3215498B1 (fr) |
| JP (1) | JP6623220B2 (fr) |
| KR (1) | KR20170081178A (fr) |
| CN (1) | CN107074783B (fr) |
| AR (1) | AR102487A1 (fr) |
| AU (1) | AU2015342017B2 (fr) |
| BR (1) | BR112017009204A2 (fr) |
| CA (1) | CA2966256A1 (fr) |
| CL (1) | CL2017001087A1 (fr) |
| CO (1) | CO2017004471A2 (fr) |
| CU (1) | CU24462B1 (fr) |
| CY (1) | CY1120941T1 (fr) |
| DK (1) | DK3215498T3 (fr) |
| DO (1) | DOP2017000109A (fr) |
| EA (1) | EA032137B1 (fr) |
| EC (1) | ECSP17026733A (fr) |
| ES (1) | ES2697902T3 (fr) |
| GT (1) | GT201700094A (fr) |
| HR (1) | HRP20181742T1 (fr) |
| HU (1) | HUE040696T2 (fr) |
| IL (1) | IL251354B (fr) |
| JO (1) | JO3503B1 (fr) |
| LT (1) | LT3215498T (fr) |
| MA (1) | MA40893B1 (fr) |
| MX (1) | MX375779B (fr) |
| MY (1) | MY186908A (fr) |
| PE (1) | PE20170945A1 (fr) |
| PH (1) | PH12017500802A1 (fr) |
| PL (1) | PL3215498T3 (fr) |
| PT (1) | PT3215498T (fr) |
| RS (1) | RS58049B1 (fr) |
| SA (1) | SA517381429B1 (fr) |
| SG (1) | SG11201703199UA (fr) |
| SI (1) | SI3215498T1 (fr) |
| SV (1) | SV2017005426A (fr) |
| TW (1) | TWI694072B (fr) |
| UY (1) | UY36383A (fr) |
| WO (1) | WO2016071212A1 (fr) |
| ZA (1) | ZA201703802B (fr) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2539326B1 (fr) | 2010-02-27 | 2017-05-03 | Bayer Intellectual Property GmbH | Aryltriazolone liée à un bis-aryle et son utilisation |
| US10138236B2 (en) | 2014-09-24 | 2018-11-27 | Bayer Pharma Aktiengesellschaft | Factor xia-inhibiting pyridobenzazepine and pyridobenzazocine derivatives |
| UY36714A (es) | 2015-06-09 | 2016-12-30 | Bayer Pharma Akttiengesellschaft | Moduladores alostéricos positivos del receptor muscarínico m2 |
| US9988367B2 (en) | 2016-05-03 | 2018-06-05 | Bayer Pharma Aktiengesellschaft | Amide-substituted pyridinyltriazole derivatives and uses thereof |
| WO2017191105A1 (fr) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Dérivés d'aryltriazole à substitution amide et leurs utilisations |
| US10815205B2 (en) | 2016-05-03 | 2020-10-27 | Bayer Pharma Aktiengesellschaft | Amide-substituted phenyltriazole derivatives and uses thereof |
| CN109071464A (zh) * | 2016-05-03 | 2018-12-21 | 拜耳制药股份公司 | 氧代烷基取代的苯基三唑衍生物及其用途 |
| WO2017191112A1 (fr) * | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Dérivés d'aryltriazole à substitution fluoroalkyle et utilisations desdits dérivés |
| US10526314B2 (en) | 2016-05-03 | 2020-01-07 | Bayer Aktiengesellschaft | Hydroxyalkyl-substituted heteroaryltriazole derivatives and uses thereof |
| WO2017191117A1 (fr) | 2016-05-03 | 2017-11-09 | Bayer Pharma Aktiengesellschaft | Antagonistes du récepteur v1a destinés à une utilisation dans le traitement de maladies rénales |
| US10703742B2 (en) * | 2016-05-03 | 2020-07-07 | Bayer Pharma Aktiengesellschaft | Method for producing 5-hydroxyalkyl-substituted 1-phenyl-1,2,4-triazole derivatives |
| CA3030204A1 (fr) | 2016-07-11 | 2018-01-18 | Bayer Pharma Aktiengesellschaft | Amides de l'acide 1-pyridyl-naphthyridin-3-carboxylique substitues en position 7, et leur utilisation |
| JOP20190045A1 (ar) | 2016-09-14 | 2019-03-14 | Bayer Ag | مركبات أميد حمض 1- أريل-نفثيريدين-3-كربوكسيليك مستبدلة في الموضع 7 واستخدامها. |
| EP3296298A1 (fr) | 2016-09-14 | 2018-03-21 | Bayer Pharma Aktiengesellschaft | 1-aryl-naphtyridin-3-ylcarboxamides substitués en position 7 et leur utilisation |
| JOP20190080A1 (ar) | 2016-10-14 | 2019-04-11 | Bayer Pharma AG | مركبات مشتقة من 6-(1h-بيرازول-1-يل) بيريميدين-4- أمين مستبدل واستخداماتها |
| US10927098B2 (en) | 2016-10-20 | 2021-02-23 | Bayer Pharma Aktiengesellschaft | Hydroxyalkyl-substituted triazole derivatives and uses thereof |
| WO2018149929A1 (fr) * | 2017-02-16 | 2018-08-23 | Bayer Pharma Aktiengesellschaft | Dosages de gènes rapporteurs et analyse transcriptionnelle combinés |
| CA3079771A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Derives de triazole substitues et utilisations associees |
| WO2019081307A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Dérivés de triazole substitués et utilisations associées |
| US11149023B2 (en) | 2017-10-24 | 2021-10-19 | Bayer Pharma Aktiengesellschaft | Substituted triazole derivatives and uses thereof |
| US11298367B2 (en) * | 2017-10-24 | 2022-04-12 | Bayer Aktiengesellschaft | Prodrugs of substituted triazole derivatives and uses thereof |
| WO2019081291A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Promédicaments de dérivés de triazole substitués, et utilisations de ceux-ci |
| WO2019081353A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Aktiengesellschaft | Imidazopyridinamides substituées et leur utilisation |
| WO2019081302A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Dérivés de triazole substitués et utilisations associées |
| WO2019081299A1 (fr) | 2017-10-24 | 2019-05-02 | Bayer Pharma Aktiengesellschaft | Dérivés de triazole substitués par une amine et utilisations associées |
| US20200337590A1 (en) | 2018-01-16 | 2020-10-29 | Bayer Aktiengesellschaft | Assistance in the treatment of cardiac insufficiency |
| EP3553079A1 (fr) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Anticorps greffés de peptide natriurétique de type c |
| EP3553082A1 (fr) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Anticorps greffés de peptide natriurétique du cerveau |
| EP3553081A1 (fr) | 2018-04-12 | 2019-10-16 | Bayer Aktiengesellschaft | Anticorps greffés de peptide natriurétique auriculaire |
| JOP20200287A1 (ar) | 2018-05-15 | 2020-11-09 | Bayer Ag | بنزاميدات مستبدلة بـ 3،1- ثيازول-2- يل للمعالجة من أمراض مصاحبة لتحسس الألياف العصبية |
| AU2019270142A1 (en) | 2018-05-17 | 2020-11-12 | Bayer Aktiengesellschaft | Substituted dihydropyrazolo pyrazine carboxamide derivatives |
| WO2020216669A1 (fr) | 2019-04-23 | 2020-10-29 | Bayer Aktiengesellschaft | Imidazopyridinamides substitués par un phényle et leur utilisation |
| CN110082451B (zh) * | 2019-05-23 | 2021-12-24 | 南京趣酶生物科技有限公司 | 一种2-氯-1-(6-氟-色满-2-)乙醇手性醇中间体制备过程的sfc检测方法 |
| WO2021094210A1 (fr) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Dérivés de pyrazine carboxamide substitués utilisés en tant qu'antagonistes du récepteur de la prostaglandine ep3 |
| WO2021094208A1 (fr) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Antagonistes d'imidazo pyrimidine ep3 substitués |
| WO2021094209A1 (fr) | 2019-11-12 | 2021-05-20 | Bayer Aktiengesellschaft | Dérivés de pyrrolo triazine carboxamide substitués en tant qu'antagonistes du récepteur de la prostaglandine ep3 |
| EP3822265A1 (fr) | 2019-11-15 | 2021-05-19 | Bayer AG | Hydantoïnamides substitués comme antagonistes d'adamts7 |
| EP3822268A1 (fr) | 2019-11-15 | 2021-05-19 | Bayer Aktiengesellschaft | Hydantoinamides substitués comme antagonistes d'adamts7 |
| EP3900722A1 (fr) | 2020-04-22 | 2021-10-27 | Bayer AG | Association de finerenone et de pecavaptan pour le traitement et / ou la prevention des maladies cardiovasculaires et / ou renales |
| CA3180674A1 (fr) | 2020-04-22 | 2021-10-28 | Bayer Aktiengesellschaft | Combinaison de finerenone et d'un inhibiteur de sglt2 pour le traitement et/ou la prevention de maladies cardiovasculaires et/ou renales |
| WO2021259852A1 (fr) | 2020-06-25 | 2021-12-30 | Bayer Aktiengesellschaft | Procédé de préparation de dérivés de 5-(alcoxycarbonyle)-et de 5- (carboxamide)-1-aryl-1,2,4-triazole |
| WO2022112213A1 (fr) | 2020-11-30 | 2022-06-02 | Bayer Aktiengesellschaft | Formes cristallines de 3-[[3-(4-chlorophényl)-5-oxo-4-((2s)-3,3,3-trifluoro-2-hydroxypropyl)-4,5-dihydro-1h-1,2,4-triazol-1-yl]méthyl]-1-[3- (trifluorométhyl)pyridin-2-yl]-1h-1,2,4-triazole-5-carboxamide |
| EP4011874A1 (fr) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Acides carboxyliques de pyrazolo pipéridine substitués |
| EP4011873A1 (fr) | 2020-12-10 | 2022-06-15 | Bayer Aktiengesellschaft | Acides carboxyliques de pyrazolo pipéridine substitués |
| WO2022122914A1 (fr) | 2020-12-10 | 2022-06-16 | Bayer Aktiengesellschaft | Acides pyrazolo pipéridine carboxyliques substitués |
| CN116829545A (zh) | 2020-12-10 | 2023-09-29 | 拜耳公司 | 取代的吡唑基哌啶羧酸 |
| KR20230118143A (ko) | 2020-12-10 | 2023-08-10 | 바이엘 악티엔게젤샤프트 | 안과 질환의 치료를 위한 sGC 활성화제의 용도 |
| CN114835688B (zh) * | 2021-02-02 | 2024-08-06 | 深圳信立泰药业股份有限公司 | 一种取代的4-芳基咪唑-2-酮衍生物及其制备方法和医药用途 |
| WO2022214206A1 (fr) | 2021-04-08 | 2022-10-13 | Bayer Aktiengesellschaft | Combinaison de finérénone et de pecavaptan pour le traitement et/ou la prévention de maladies cardiovasculaires et/ou rénales |
| JP2025518350A (ja) | 2022-06-09 | 2025-06-12 | バイエル・アクチエンゲゼルシヤフト | 女性における駆出率が維持された心不全の治療に使用するための可溶性グアニル酸シクラーゼアクチベーター |
| WO2025224069A1 (fr) | 2024-04-23 | 2025-10-30 | Bayer Aktiengesellschaft | Co-cristaux de finérénone, de pecavaptan et d'inhibiteurs de sglt2 |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3042466A1 (de) | 1980-11-11 | 1982-06-16 | A. Nattermann & Cie GmbH, 5000 Köln | N-substituierte (omega) -(2-oxo-4-imidazolin-l-yl)-alkansaeure-derivate, verfahren zu ihrer herstellung und diese enthaltende pharmazeutische praeparate |
| US5468448A (en) | 1989-12-28 | 1995-11-21 | Ciba-Geigy Corporation | Peroxide disinfection method and devices therefor |
| DE4107857A1 (de) | 1991-03-12 | 1992-09-17 | Thomae Gmbh Dr K | Cyclische harnstoffderivate, diese verbindungen enthaltende arzneimittel und verfahren zu ihrer herstellung |
| CA2109524A1 (fr) | 1991-05-10 | 1992-11-11 | Prasun K. Chakravarty | Derives acides d'aralkyltriazole, antagonistes de l'angiotensine ii |
| US5326776A (en) | 1992-03-02 | 1994-07-05 | Abbott Laboratories | Angiotensin II receptor antagonists |
| SK94393A3 (en) | 1992-09-11 | 1994-08-10 | Thomae Gmbh Dr K | Cyclic derivatives of urea, process for their production and their pharmaceutical agents with the content of those |
| GB9301192D0 (en) | 1993-06-09 | 1993-06-09 | Trott Francis W | Flower shaped mechanised table |
| US6844005B2 (en) | 2002-02-25 | 2005-01-18 | Trutek Corp | Electrostatically charged nasal application product with increased strength |
| FR2708608B1 (fr) | 1993-07-30 | 1995-10-27 | Sanofi Sa | Dérivés de N-sulfonylbenzimidazolone, leur préparation, les compositions pharmaceutiques en contenant. |
| US5897858A (en) | 1994-02-03 | 1999-04-27 | Schering-Plough Healthcare Products, Inc. | Nasal spray compositions exhibiting increased retention in the nasal cavity |
| US20010020100A1 (en) | 1994-06-14 | 2001-09-06 | G.D. Searle & Co. | N-substituted-1, 2, 4-triazolone compounds for treatment of cardiovascular disorders |
| SI1040111T1 (en) | 1997-12-17 | 2005-10-31 | Merck & Co., Inc. | Integrin receptor antagonists |
| DE19816882A1 (de) | 1998-04-17 | 1999-10-21 | Boehringer Ingelheim Pharma | Triazolone mit neuroprotektiver Wirkung |
| JP2002521373A (ja) | 1998-07-24 | 2002-07-16 | バイエル アクチェンゲゼルシャフト | 置換されたベンゾイルシクロヘキサンジオン類 |
| DE19834044A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Neue substituierte Pyrazolderivate |
| DE19834047A1 (de) | 1998-07-29 | 2000-02-03 | Bayer Ag | Substituierte Pyrazolderivate |
| DE19914140A1 (de) | 1999-03-27 | 2000-09-28 | Bayer Ag | Substituierte Benzoylpyrazole |
| KR20020005653A (ko) | 1999-04-01 | 2002-01-17 | 실버스타인 아써 에이. | 소르비톨 디하이드로게나제 저해제로서의 아미노피리미딘 |
| DE19920791A1 (de) | 1999-05-06 | 2000-11-09 | Bayer Ag | Substituierte Benzoylisoxazole |
| DE19921424A1 (de) | 1999-05-08 | 2000-11-09 | Bayer Ag | Substituierte Benzoylketone |
| DE19929348A1 (de) | 1999-06-26 | 2000-12-28 | Bayer Ag | Verfahren zur Herstellung von 2-Heterocyclylmethyl-benzoesäurederivaten |
| US6531142B1 (en) | 1999-08-18 | 2003-03-11 | The Procter & Gamble Company | Stable, electrostatically sprayable topical compositions |
| DE19943635A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943634A1 (de) | 1999-09-13 | 2001-04-12 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE19943639A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Dicarbonsäurederivate mit neuartigen pharmazeutischen Eigenschaften |
| DE19943636A1 (de) | 1999-09-13 | 2001-03-15 | Bayer Ag | Neuartige Dicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| AR027575A1 (es) | 2000-03-06 | 2003-04-02 | Bayer Ag | Benzoilciclohexenonas substituidas |
| US7080644B2 (en) | 2000-06-28 | 2006-07-25 | Microdose Technologies, Inc. | Packaging and delivery of pharmaceuticals and drugs |
| AR031176A1 (es) | 2000-11-22 | 2003-09-10 | Bayer Ag | Nuevos derivados de pirazolpiridina sustituidos con piridina |
| WO2002066447A1 (fr) | 2001-02-21 | 2002-08-29 | Ono Pharmaceutical Co., Ltd. | Derives de 4h-1,2,4-triazole-3(2h)-thione tenant lieu d'inhibiteurs de sphingomyelinase |
| DE10110750A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Neuartige Aminodicarbonsäurederivate mit pharmazeutischen Eigenschaften |
| DE10110749A1 (de) | 2001-03-07 | 2002-09-12 | Bayer Ag | Substituierte Aminodicarbonsäurederivate |
| US20040071757A1 (en) | 2001-11-20 | 2004-04-15 | David Rolf | Inhalation antiviral patch |
| DE10220570A1 (de) | 2002-05-08 | 2003-11-20 | Bayer Ag | Carbamat-substituierte Pyrazolopyridine |
| WO2004083187A1 (fr) | 2003-03-14 | 2004-09-30 | Merck & Co. Inc. | Antagonistes des recepteurs du cgrp d'anilide spirohydantoine monocyclique |
| WO2005006892A2 (fr) | 2003-06-27 | 2005-01-27 | Berglin Corporation Of Washington | Machine permettant de noyauter et trancher avec precision et avec une faible contrainte les pommes et autres fruits a coeur tendre ou a noyau |
| GEP20084571B (en) * | 2003-12-22 | 2008-12-25 | Pfizer | Triazole derivatives as vasopressin antagonists |
| US20070281937A1 (en) | 2004-03-08 | 2007-12-06 | Robert Zelle | Ion Channel Modulators |
| US20080139560A1 (en) | 2004-03-08 | 2008-06-12 | Scion Pharmaceuticals, Inc. | Ion Channel Modulators |
| EP1742932A1 (fr) * | 2004-04-28 | 2007-01-17 | Pfizer Limited | Derives 3-heterocyclyl-4-phenyl-triazole comme inhibiteurs de la vasopressine par recepteur |
| JP2008524246A (ja) | 2004-12-16 | 2008-07-10 | タケダ サン ディエゴ インコーポレイテッド | ヒストンデアセチラーゼ阻害剤 |
| WO2006117657A1 (fr) | 2005-05-03 | 2006-11-09 | Ranbaxy Laboratories Limited | Derives de triazolone utilises comme agents anti-inflammatoires |
| DE102006024024A1 (de) | 2006-05-23 | 2007-11-29 | Bayer Healthcare Aktiengesellschaft | Substituierte Arylimidazolone und -triazolone sowie ihre Verwendung |
| NZ580637A (en) * | 2007-04-26 | 2011-07-29 | Lundbeck & Co As H | Isoquinolinone derivatives as nk3 antagonists |
| DE102008060967A1 (de) | 2008-12-06 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylsulfonyltriazolone und ihre Verwendung |
| DE102009013642A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte Phenylalaninderivate und deren Verwendung |
| DE102010001064A1 (de) | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| DE102009028929A1 (de) | 2009-08-27 | 2011-07-07 | Bayer Schering Pharma Aktiengesellschaft, 13353 | Heterocyclisch-substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
| EP2539326B1 (fr) * | 2010-02-27 | 2017-05-03 | Bayer Intellectual Property GmbH | Aryltriazolone liée à un bis-aryle et son utilisation |
| DE102010021637A1 (de) | 2010-05-26 | 2011-12-01 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 5-Fluor-1H-Pyrazolopyridine und ihre Verwendung |
| EP2708539A1 (fr) | 2010-07-09 | 2014-03-19 | Bayer Intellectual Property GmbH | Pyrimidine et triazine condensés et leur utilisation |
| DE102010040187A1 (de) | 2010-09-02 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Substituierte N-Phenethyl-triazolonacetamide und ihre Verwendung |
| DE102010040233A1 (de) | 2010-09-03 | 2012-03-08 | Bayer Schering Pharma Aktiengesellschaft | Bicyclische Aza-Heterocyclen und ihre Verwendung |
| DE102010043379A1 (de) | 2010-11-04 | 2012-05-10 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 6-Fluor-1H-Pyrazolo[4,3-b]pyridine und ihre Verwendung |
| JP2015514063A (ja) | 2012-03-22 | 2015-05-18 | ビオタ ヨーロッパ リミテッドＢｉｏｔａ Ｅｕｒｏｐｅ Ｌｔｄ | 抗菌化合物 |
| AP2016009128A0 (en) * | 2013-10-07 | 2016-04-30 | Bayer Pharma AG | Cyclic thienouracil-carboxamides and use thereof |
-
2015
- 2015-10-30 JP JP2017523872A patent/JP6623220B2/ja not_active Expired - Fee Related
- 2015-10-30 KR KR1020177011653A patent/KR20170081178A/ko not_active Withdrawn
- 2015-10-30 SI SI201530445T patent/SI3215498T1/sl unknown
- 2015-10-30 CU CU2017000057A patent/CU24462B1/es unknown
- 2015-10-30 MA MA40893A patent/MA40893B1/fr unknown
- 2015-10-30 PE PE2017000788A patent/PE20170945A1/es unknown
- 2015-10-30 LT LTEP15788389.3T patent/LT3215498T/lt unknown
- 2015-10-30 ES ES15788389T patent/ES2697902T3/es active Active
- 2015-10-30 BR BR112017009204-2A patent/BR112017009204A2/pt not_active Application Discontinuation
- 2015-10-30 MX MX2017005479A patent/MX375779B/es active IP Right Grant
- 2015-10-30 HU HUE15788389A patent/HUE040696T2/hu unknown
- 2015-10-30 CN CN201580059512.8A patent/CN107074783B/zh not_active Expired - Fee Related
- 2015-10-30 US US15/523,061 patent/US20170313665A1/en not_active Abandoned
- 2015-10-30 HR HRP20181742TT patent/HRP20181742T1/hr unknown
- 2015-10-30 DK DK15788389.3T patent/DK3215498T3/en active
- 2015-10-30 AR ARP150103529A patent/AR102487A1/es unknown
- 2015-10-30 PT PT15788389T patent/PT3215498T/pt unknown
- 2015-10-30 EA EA201790951A patent/EA032137B1/ru not_active IP Right Cessation
- 2015-10-30 EP EP15788389.3A patent/EP3215498B1/fr active Active
- 2015-10-30 PL PL15788389T patent/PL3215498T3/pl unknown
- 2015-10-30 AU AU2015342017A patent/AU2015342017B2/en not_active Ceased
- 2015-10-30 SG SG11201703199UA patent/SG11201703199UA/en unknown
- 2015-10-30 WO PCT/EP2015/075200 patent/WO2016071212A1/fr not_active Ceased
- 2015-10-30 RS RS20181378A patent/RS58049B1/sr unknown
- 2015-10-30 CA CA2966256A patent/CA2966256A1/fr not_active Abandoned
- 2015-10-30 MY MYPI2017701506A patent/MY186908A/en unknown
- 2015-10-30 TW TW104135707A patent/TWI694072B/zh not_active IP Right Cessation
- 2015-10-30 UY UY0001036383A patent/UY36383A/es not_active Application Discontinuation
- 2015-11-02 US US14/930,157 patent/US9771352B2/en not_active Expired - Fee Related
- 2015-11-02 JO JOP/2015/0271A patent/JO3503B1/ar active
-
2017
- 2017-03-23 IL IL251354A patent/IL251354B/en active IP Right Grant
- 2017-04-26 SV SV2017005426A patent/SV2017005426A/es unknown
- 2017-04-27 PH PH12017500802A patent/PH12017500802A1/en unknown
- 2017-04-27 SA SA517381429A patent/SA517381429B1/ar unknown
- 2017-04-28 DO DO2017000109A patent/DOP2017000109A/es unknown
- 2017-04-28 EC ECIEPI201726733A patent/ECSP17026733A/es unknown
- 2017-05-02 CL CL2017001087A patent/CL2017001087A1/es unknown
- 2017-05-03 CO CONC2017/0004471A patent/CO2017004471A2/es unknown
- 2017-05-03 GT GT201700094A patent/GT201700094A/es unknown
- 2017-06-02 ZA ZA2017/03802A patent/ZA201703802B/en unknown
-
2018
- 2018-11-19 CY CY181101217T patent/CY1120941T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA40893B1 (fr) | Dérivés de phényltriazole à substitution hydroxyalkyle et utilisations associées | |
| MA44851B1 (fr) | Dérivés pyridinyltriazole substitués par des groupements amides et leurs utilisations | |
| MA64509B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA64121B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA42376A (fr) | Dérivés d'oxopyridine substitués | |
| MA43335B1 (fr) | Compositions d'arni de transthyrétine (ttr) et procédés pour les utiliser pour le traitement ou la prévention de maladies associées à ttr | |
| MA32226B1 (fr) | Compositions et leurs procedes de preparation et d'utilisation | |
| MA41238A (fr) | Dérivés 5-[(pipérazin-1-yl)-3-oxo-propyl]-imidazolidine-2,4-dione en tant qu'inhibiteurs d'adamts pour le traitement de l'ostéoarthrit | |
| MA34545B1 (fr) | Co-cristaux et sels d'inhibiteurs de ccr3 | |
| MA40875B1 (fr) | 2,4-diamino-quinoléine substituée servant de nouveaux agents anticancéreux | |
| MA37742B1 (fr) | Dérivés d'oestra-1,3,5 (10), 16-tétraène substitués en position 3, leurs procédés de préparation, préparations pharmaceutiques les contenant, et leur utilisation pour la fabrication de médicaments | |
| MA38358A1 (fr) | Formulations de composés organiques | |
| MA39170A1 (fr) | Composes inhibiteurs de sérine/thréonine kinase pour leurs utilisations dans le traitement du cancer | |
| MA40366A (fr) | Dérivés de tétrahydroquinoline à titre d'inhibiteurs des bromodomaines | |
| MA38925A1 (fr) | Dérivés de phénylalanine substitués | |
| MA44965A (fr) | Dérivés de pyridinyle, compositions pharmaceutiques et utilisations de ceux-ci en tant qu'inhibiteurs d'aoc3 | |
| MA43250B1 (fr) | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues | |
| MA45609B1 (fr) | Compositions d'acide cromoglicique pour le traitement de la dermatite | |
| MX2021000475A (es) | Isoxazol como agonista del receptor fxr. | |
| MA49994B1 (fr) | Composés macrocycliques pour le traitement de maladie | |
| FR3042191B1 (fr) | Derives 1,4,8-triazaphenanthrene pour le traitement de maladies neurodegeneratives | |
| MA39446A1 (fr) | Compositions pharmaceutiques pour traiter des maladies infecteuses | |
| FR3103702B1 (fr) | Utilisation de NMN pour la prévention et/ou le traitement de la spondylarthrite ankylosante et compositions correspondantes | |
| MA43263B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs | |
| MA44144B1 (fr) | Composés hétérocycliques utilisés comme immunomodulateurs |